NasdaqGM - Nasdaq Real Time Price USD

Larimar Therapeutics, Inc. (LRMR)

2.2500
-0.0500
(-2.17%)
At close: May 30 at 4:00:02 PM EDT
2.1600
-0.09
(-4.00%)
After hours: May 30 at 6:39:22 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Carole S. Ben-Maimon M.D. CEO, President & Director 905.66k -- 1959
Mr. Michael Celano CPA Secretary & CFO 625.73k -- 1959
Dr. Gopi Shankar M.B.A., Ph.D. Chief Development Officer 618.66k -- 1971
Mr. John Berman Vice President of Finance & Administration -- -- --
Ms. Jennifer Spokes Johansson Vice President of Legal & Compliance -- -- --
Dr. Russell G. Clayton Sr., D.O, D.O. Chief Medical Officer -- -- 1961
Mr. Francis Michael Conway CPA VP & Controller -- -- --

Larimar Therapeutics, Inc.

Three Bala Plaza East
Suite 506
Bala Cynwyd, PA 19004
United States
844-511-9056 https://larimartx.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
65

Description

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Corporate Governance

Larimar Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2025 is 8. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 5, 2025 at 12:30 PM UTC - August 11, 2025 at 12:30 PM UTC

Larimar Therapeutics, Inc. Earnings Date

Recent Events

May 13, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 5, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

April 30, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 11, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

March 24, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 27, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 16, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 18, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

Related Tickers